AstraZeneca Building Japan Presence Ahead Of Crestor Loss
This article was originally published in PharmAsia News
Executive Summary
Phase III results are expected soon for a Japanese study of Brilinta, and the company hopes to have a fresh start for a new, but slow-growing product.